Furthermore, in a spontaneous in vivo model of breast cancer, cancer cells stimulate systemic inflammation by producing IL-1β, which leads to stimulation of IL-17 production by γδT cells [57] and can inhibit anti-tumor CD8+ T cell activity [57]. This evidence concerns the gene CD8A and neoplasm.